Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study

Fig. 3

Change in ACR components from baseline to weeks 4, 8, 12, 24, and 52: (A) SJC, (B) TJC, (C) PtGA VAS, (D) patient pain VAS, (E) PGA VAS, (F) HAQ-DI, (G) CRP, and (H) ESR. Results are presented as the mean ± 95% confidence interval: (i) baricitinib 2 mg in the morning vs. baricitinib 2 mg in the evening, n = 50, 51, (ii) baricitinib 4 mg in the morning vs. baricitinib 4 mg in the evening, n = 52, 53, respectively

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us